Genetic diseases caused by nonsense mutations—where DNA changes create premature stop signals during protein production—affect millions worldwide yet remain largely untreatable. This therapeutic gap persists because cells interpret these faulty stop codons as legitimate instructions to halt protein synthesis, leaving patients with truncated, non-functional proteins that drive devastating conditions like cystic fibrosis and Duchenne muscular dystrophy. Recent advances in transfer RNA engineering now offer a promising workaround by modifying the cellular machinery that reads genetic instructions. The approach involves editing tRNA genes to create suppressor variants that can override nonsense mutations by inserting amino acids where cells would normally terminate protein production. This allows full-length, functional proteins to be synthesized despite the underlying genetic defects. The strategy represents a departure from traditional gene therapy, which typically requires replacing entire faulty genes—a complex undertaking given the size and regulatory complexity of many disease-associated genes. Instead, tRNA suppression targets the translation machinery itself, potentially addressing multiple genetic variants with a single therapeutic intervention. While promising in laboratory settings, this approach faces significant hurdles including delivery challenges and the need to achieve precise suppression efficiency. Too little suppression fails to restore protein function, while excessive suppression could interfere with normal cellular processes that rely on proper stop codon recognition. The field remains in early stages, but successful tRNA editing could fundamentally expand treatment options for the estimated 10-15% of genetic diseases caused by nonsense mutations, offering hope for conditions previously considered therapeutically intractable.